<DOC>
	<DOCNO>NCT00000920</DOCNO>
	<brief_summary>The purpose study see safe give saquinavir-SGC ( SQV ) combine low-dose ritonavir ( RTV ) plus zidovudine ( ZDV ) lamivudine ( 3TC ) HIV-positive pregnant woman see safe give 3TC ZDV newborn . Another purpose see level SQV , low-dose RTV , ZDV , 3TC find mother level ZDV 3TC see newborn . Another purpose study see whether SQV pass mother newborn pass level safe newborn . Although ZDV able reduce rate transmission HIV mother child , may possible reduce use combination anti-HIV drug . This study add SQV ( protease inhibitor [ PI ] ) RTV ( another PI ) 3TC ( reverse transcriptase inhibitor ) mother 's ZDV regimen .</brief_summary>
	<brief_title>Fortovase ( Saquinavir ) Given With Low-Dose Ritonavir , Zidovudine , Lamivudine HIV-Positive Pregnant Women During After Pregnancy Their Newborns</brief_title>
	<detailed_description>Although administration ZDV mother-infant pair dramatically reduce perinatal HIV infection , goal reduce less 2 % . In order achieve , combination strategy need developed 2 purpose : 1 ) reduce perinatal transmission rate goal level ; 2 ) provide combination therapy HIV-infected mother whose virus become resistant ZDV , high viral load , previously transmit HIV ZDV . This study add 3TC ( another reverse transcriptase inhibitor ) SQV ( protease inhibitor [ PI ] ) [ AS PER AMENDMENT 08/15/00 : low-dose RTV ( another PI ) ] mother 's ZDV regimen . During antepartum period , mother receive SQV [ AS PER AMENDMENT 08/15/00 : low-dose RTV plus ] ZDV 3TC . At onset active labor , mother receive load dos study drug , receive study drug 12 week postpartum schedule antenatal period . Within 12 hour delivery , infant begin receive 3TC ZDV continue 6 week age . Mothers follow 12 week postpartum baby follow 6 month age . [ AS PER AMENDMENT 02/09/99 : For maternal dosing , 1 Combivir tablet ( contain 3TC ZDV ) may administer place individual agent 3TC ZDV . Patients prematurely discontinue study treatment continue follow duration study . ]</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Are 14 32 week pregnant . Are least 13 year old ( need consent parent guardian 18 ) . Exclusion Criteria Patients may eligible study : Can take ZDV , 3TC , high dos RTV . Women able tolerate low dos RTV may eligible . Are pregnant 1 baby . ( This study change patient pregnant 1 baby eligible . ) Have pregnancy complication medical problem put pregnancy risk . Have active opportunistic ( HIVrelated ) infection and/or serious bacterial infection study entry . Have chronic diarrhea . Abuse alcohol drug . Do access participate clinic willing follow clinic duration study . Have receive certain antiretroviral ( antiHIV ) drug take certain medication . ( This study change increase enrollment . The eligibility criterion earlier version restrictive , change include woman receive SQV [ without RTV ] , 3TC , ZDV longer 3 week preentry viral load 400 copies/ml less OR significant reduction viral load within 90 day preentry visit . ) Plan breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pregnancy</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Pregnancy Complications</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>